New Anticoagulants for Atrial Fibrillation

The authors regret the following two errors published in the above article in Seminars in Thrmbosis and Hemostasis, Volume 35, Number 5: On page 515, line five of the abstract, “These drugs have minimal protein binding and predictable pharmacokinetics that allow fixed dosing without laboratory monitoring and are being compared with vitamin K antagonists or aspirin in phase III clinical trials”, is incorrect. This line should read “These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials”. On page 516, column one, under heading “New Anticoagulants”, line three, “The new anticoagulants are all small synthetic molecules with advantages that include minimal protein binding, predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring”, is incorrect. This line should read “The new anticoagulants are all small synthetic molecules with advantages that include predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring”.